Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSH | P09668 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PEPD | P12955 | 2/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 10/20 | 0.41 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856059 | 1.00 | CTSL (0.56) | CTSLCTSBCTSHCTSKPOLB | |
| SCHEMBL6856402 | 0.89 | CTSK (0.52) | CTSLCTSBCTSHCTSKPOLB | |
| SCHEMBL555492 | 0.84 | POLB (0.45) | CTSLCTSBCTSHCTSKPOLB | |
| SCHEMBL20308345 | 0.82 | POLB (0.44) | CTSLCTSBCTSHCTSKPOLB | |
| SCHEMBL6884054 | 0.77 | CTSL (0.47) | CTSLCTSBCTSHCTSKUCHL1 | |
| SCHEMBL707281 | 0.77 | CTSL (0.47) | CTSLCTSBCTSHCTSKUCHL1 | |
| SCHEMBL707280 | 0.77 | CTSL (0.47) | CTSLCTSBCTSHCTSKUCHL1 | |
| SCHEMBL28356288 | 0.77 | CTSK (0.51) | CTSLCTSBCTSHCTSKUCHL1 | |
| SCHEMBL2224182 | 0.75 | LTA4H (0.43) | CTSLCTSBCTSHCTSKPOLB | |
| SCHEMBL2224603 | 0.75 | LTA4H (0.43) | CTSLCTSBCTSHCTSKPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | CTSL 627/4885CTSB 320/4885CTSH 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.